October 24, 2013
by admin
12 Comments
The asset-centric platform at Index Ventures is built around stringency. The entire concept arose from the realization that drug discovery and development is a complex process, in a low-validity environment (meaning there is often too little data available to make … Continue reading
October 16, 2013
by admin
0 comments
Today, the majority of clinical trials that are run never report their results in a form that is accessible to the public. To many people that is unacceptable for several reasons: it makes it possible for drug companies to selectively … Continue reading
October 2, 2013
by admin
6 Comments
Late-stage attrition kills returns on pharma R&D investment. One way to reduce attrition is to take less risk – incremental innovation reduces the risk of failing in development, but increases the risk of failing in the marketplace with even bigger … Continue reading